Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms
NCT ID: NCT02580903
Last Updated: 2020-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
180 participants
OBSERVATIONAL
2015-02-28
2020-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
All patients attending our department with the above mentioned neoplasms will be offered inclusion in this study. All will have an echo performed and patients identified as being at risk of pulmonary hypertension will be offered complete investigation as specified by the European Cardiology Association.
All patients will be followed up for a total of five years to identify prognosis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence and Risk Factors of Pulmonary Hypertension in Patients with Myeloproliferative Neoplasms in Assiut University Hospital.
NCT06647706
Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases
NCT01787162
The Study Of CT Scans and Echo Parameters in Patients With PAH
NCT00625963
Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases
NCT00909467
Prospective Registry and Biobank for Long-term Observational Studies in Adult Patients with Pulmonary Hypertension
NCT04654650
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radiology
Only a small subsample will require CT and right heart catherisation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Lack of informed consent
* Age \< 18 years
* Cognitive dysfunctions
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Odense University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mette Brabrand
Staff Specialist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mette Brabrand, MD
Role: PRINCIPAL_INVESTIGATOR
Odense University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Odense University Hospital
Odense, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MPNPH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.